BR112013007849A2 - compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitação - Google Patents
compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitaçãoInfo
- Publication number
- BR112013007849A2 BR112013007849A2 BR112013007849A BR112013007849A BR112013007849A2 BR 112013007849 A2 BR112013007849 A2 BR 112013007849A2 BR 112013007849 A BR112013007849 A BR 112013007849A BR 112013007849 A BR112013007849 A BR 112013007849A BR 112013007849 A2 BR112013007849 A2 BR 112013007849A2
- Authority
- BR
- Brazil
- Prior art keywords
- modulating
- prevention
- treatment
- compounds capable
- cardiac arrest
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070427 | 2010-10-01 | ||
| PCT/DK2011/050375 WO2012041334A1 (en) | 2010-10-01 | 2011-09-30 | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013007849A2 true BR112013007849A2 (pt) | 2016-06-07 |
Family
ID=44872128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013007849A BR112013007849A2 (pt) | 2010-10-01 | 2011-09-30 | compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitação |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130261177A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2622354A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013543491A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140025303A (cg-RX-API-DMAC7.html) |
| CN (2) | CN106038570A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011307494B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013007849A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2812846A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012041334A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010259943C1 (en) | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| KR20140053881A (ko) * | 2011-04-19 | 2014-05-08 | 릭스하스피탈렛 | 모세관 누출의 예방 및 치료를 위한 수술 동안 투여되는 프로스타시클린 및 그 유사체 |
| EP2834642A1 (en) * | 2012-03-30 | 2015-02-11 | Rigshospitalet | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
| CN104837806A (zh) | 2012-12-07 | 2015-08-12 | 开曼化学股份有限公司 | 前列环素类似物的合成方法 |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP3712142B1 (en) * | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| WO2015073314A1 (en) | 2013-11-13 | 2015-05-21 | Cayman Chemical Company Incorporated | Amine salts of a prostacyclin analog |
| WO2016073668A1 (en) | 2014-11-06 | 2016-05-12 | The Regents Of The University Of Colorado | Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent |
| CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| CN107430136A (zh) * | 2015-02-03 | 2017-12-01 | 科罗拉多州立大学董事会,公司实体 | 粘弹性分析用于预测大量出血的用途 |
| DK3278112T3 (da) | 2015-03-29 | 2021-12-13 | Endothel Pharma Aps | Sammensætning, der omfatter prostacyclin eller analoger deraf, til behandling af akut, kritisk syge patienter |
| WO2016200765A1 (en) | 2015-06-08 | 2016-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Time independent viscoelastic analysis parameter for prediction of patient outcome |
| US11169142B2 (en) | 2016-05-11 | 2021-11-09 | The Regents Of The University Of Colorado, A Body Corporate | Viscoelastic analysis in patients with disease associated with cardiovascular system |
| US10806801B2 (en) * | 2017-06-07 | 2020-10-20 | National Cheng Kung University | Pharmaceutical composition and methods for using the same |
| WO2021062298A1 (en) | 2019-09-27 | 2021-04-01 | Arterez, Inc. | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
| US12440285B2 (en) * | 2021-01-22 | 2025-10-14 | Cilag Gmbh International | Prediction of hemostasis issues based on biomarker monitoring |
| US12105099B2 (en) * | 2021-04-28 | 2024-10-01 | Diotex Diagnostics, Llc | Methods and devices for quantitatively estimating syndecan-1 |
| CN114113641B (zh) * | 2021-10-28 | 2023-11-03 | 中科精瓒(武汉)医疗技术有限公司 | 一种活化凝血检测试剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58164512A (ja) * | 1982-03-25 | 1983-09-29 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤 |
| AU4405293A (en) * | 1992-06-05 | 1994-01-04 | Barbara M. Alving | Test for quantitative thrombin time |
| JPH11322612A (ja) * | 1998-03-13 | 1999-11-24 | Toray Ind Inc | 肝細胞増殖因子誘引剤 |
| CN2757804Y (zh) * | 2004-11-19 | 2006-02-15 | 杨俊玉 | 心脏按压复苏指示装置 |
| EP2063273A1 (en) * | 2007-11-21 | 2009-05-27 | Pentapharm GmbH | Method for assessing the fibrinogen contribution in coagulation |
| US20100144597A1 (en) * | 2008-12-10 | 2010-06-10 | Ward Kevin R | Novel combinatorial approaches to enhancing oxygen transport to tissues |
| CN102271685A (zh) * | 2008-12-30 | 2011-12-07 | 斯若姆博洛捷克有限公司 | 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物 |
| ES2477498T3 (es) * | 2010-01-20 | 2014-07-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular |
-
2011
- 2011-09-30 WO PCT/DK2011/050375 patent/WO2012041334A1/en not_active Ceased
- 2011-09-30 CA CA2812846A patent/CA2812846A1/en not_active Abandoned
- 2011-09-30 KR KR1020137010342A patent/KR20140025303A/ko not_active Withdrawn
- 2011-09-30 AU AU2011307494A patent/AU2011307494B2/en not_active Ceased
- 2011-09-30 BR BR112013007849A patent/BR112013007849A2/pt not_active IP Right Cessation
- 2011-09-30 JP JP2013530571A patent/JP2013543491A/ja active Pending
- 2011-09-30 EP EP11773168.7A patent/EP2622354A1/en not_active Withdrawn
- 2011-09-30 US US13/877,285 patent/US20130261177A1/en not_active Abandoned
- 2011-09-30 CN CN201610390867.1A patent/CN106038570A/zh active Pending
- 2011-09-30 CN CN201180057292.7A patent/CN103238070B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2622354A1 (en) | 2013-08-07 |
| JP2013543491A (ja) | 2013-12-05 |
| WO2012041334A1 (en) | 2012-04-05 |
| KR20140025303A (ko) | 2014-03-04 |
| CN106038570A (zh) | 2016-10-26 |
| CN103238070B (zh) | 2016-06-29 |
| CA2812846A1 (en) | 2012-04-05 |
| AU2011307494A1 (en) | 2013-05-02 |
| CN103238070A (zh) | 2013-08-07 |
| US20130261177A1 (en) | 2013-10-03 |
| AU2011307494B2 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL231654B (en) | System for remote pericardial hemostasis for ventricular access and reconstruction or other organ therapies | |
| BR112013033940A2 (pt) | terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer | |
| EP2709662A4 (en) | USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS FOR THE TREATMENT OR PREVENTION OF CHRONIC AND ACUTE FORMS OF DIARRHEA | |
| IL244995B (en) | A pharmaceutical composition containing a pcsk9 inhibitor in the treatment of hyperlipidemia | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112012031194A2 (pt) | derivados de cisteamina e seu uso no tratamento de ehna | |
| ZA201307829B (en) | Hydrocellular absorbent dressing and uses thereos for the treatemt of chronic and acute wounds | |
| IL221275A0 (en) | Sigma ligands for use in the prevention and /or treatment of postoperative pain | |
| ZA201307831B (en) | Very absorbent thin adhesive dresing and uses thereof for the treament of chronic wounds | |
| CL2015000036A1 (es) | Minerales que contienen carbonato de calcio de superficie modificada y su uso | |
| PL2905268T3 (pl) | Kompozycja do traktowania stref zaszpachlowanych gipsem, wykańczanych gipsem albo tynkowanych gipsem i jej zastosowanie do traktowania stref zaszpachlowanych gipsem, wykańczanych gipsem albo tynkowanych gipsem | |
| BR112015002706A2 (pt) | niclosamida e seus derivados para uso no tratamento de tumores sólidos | |
| BR112013014189A2 (pt) | composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções | |
| BR112014009456A2 (pt) | uso de melatonina para o tratamento e/ou prevenção de mucosite | |
| HRP20171280T1 (hr) | Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji | |
| CL2014002398A1 (es) | Formulación que comprende clonostachys rosea combinado con un silicato de calcio en partículas; y uso para tratar hongos patógenos en plantas | |
| FR2999428B1 (fr) | Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses | |
| BR112015027026A2 (pt) | composição para uso na redução da formação de crosta e na promoção da cicatrização | |
| PL2925131T3 (pl) | Synergistyczna kombinacja lenacylu i jednego spośród DCOIT lub OIT do suchej powłoki ochronnej | |
| EP2328578A4 (en) | NOSCAPIN AND NOSCAPINANALOGES AND THEIR USE IN THE TREATMENT OF INFECTIOUS DISEASES THROUGH TUBULIN BINDING INHIBITION | |
| GB201115992D0 (en) | Inhibitors of Nox4 expression and/or Nox4 function and their use in the prevention and treatment of nerve injury and/or neuropathic pain | |
| ZA201405208B (en) | A composition and use thereof in the treatment of anal rhagades | |
| PL2925132T3 (pl) | Synergistyczna kombinacja lenacylu i lPBC do suchej powłoki ochronnej | |
| EP2763673A4 (en) | USE OF INDOLYL AND INDOLINYL HYDROXAMATES FOR THE TREATMENT OF HEART FAILURE OF NERVE LESION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |